News: BDA BOD Australia secures binding letter of intent with a Swiss manufacturer, page-24

You could compare it vs other companies that have announced plans to enter the mm market but are yet to capitalize on the opportunity in the form of any product or current testing.

CMY $5m Mkt cap
ZYB $7.6m Mkt cap
BOD $10.35 Mkt cap

Obviously Mkt cap does not represent a true indication of a companies potential earnings or outcome, but it puts it a little in retrospect.

It is a matter of perspective, I would much rather have a smaller parcel in a company that is organizing relationships with $B pharma company than those other two that imo may not translate to much future success. In terms of risk tolerance vs reward 17k shares in this company if successful could turn out to be worth a lot, but isn't that the speculation game across the entire mm sector.